ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Franklin Genomic Advancements ETF
40.99
-0.0440
-0.11%
盤後：
41.11
0.1226
+0.30%
19:30 EDT
成交量：
368
成交額：
1.51萬
市值：
3,074.06萬
市盈率：
- -
高：
41.11
開：
41.11
低：
40.99
收：
41.03
52周最高：
43.51
52周最低：
29.80
股本：
75.00萬
流通股本：
75.00萬
量比：
0.21
換手率：
0.05%
股息：
0.14
股息率：
0.35%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞
公告
A股異動 | 華大智造(688114.SH)早盤漲20%封漲停 基因測序有望成為mRNA個性化腫瘤疫苗「底層基礎設施「
智通财经
·
08/20
第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司
路透中文
·
08/19
Natera助力新臨床研究：利用Latitude™評估晚期皮膚癌ctDNA動態變化
美股速递
·
08/12
韓國公布七項戰略技術項目 涵蓋核能、量子計算、太空、生物技術等領域
格隆汇
·
08/12
我國綠色燃料產業從「示範試點」走向「規模量產」
市场资讯
·
08/12
中賦科技成立靈源生物技術公司
智通财经
·
08/12
風暴眼 | 6歲女童基因治療死亡：急於追逐「全球首例」的代價
凤凰网港股
·
08/09
半月內兩起兒童基因編輯試驗死亡事件曝光，業內警示：追求「全球首創」不能忽視臨床安全與合規要求
智通财经
·
08/07
新聞8點見丨影院屏攝亂象背後的三角困局；女童基因編輯悲劇中倫理為何失守
新京报
·
08/05
AI賦能肺癌早篩診療升級 國產醫療機器人加速精準醫療落地 真健康醫療(02697)迎行業發展機遇
智通财经
·
08/04
港股異動 | 凱萊英升逾8%，近日擬向上海凱萊英生物技術發展增資10.5億元
智通财经
·
08/04
專注腫瘤領域的生物技術公司BlossomHill Therapeutics計劃通過首次公開募股募資約1.328億美元。
智通财经
·
08/04
基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具
红星资本局
·
08/03
市場消息：日本政府計劃將西日本打造為生物技術與高端醫藥領域的投資集聚中心。
智通财经
·
07/31
凱萊英(06821)擬向上海凱萊英生物技術發展增資10.5億元
智通财经
·
07/30
凱萊英(06821.HK)擬向上海凱萊英生物技術發展增資10.5億元
智通财经
·
07/30
代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元
智通财经
·
07/30
代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元
智通财经
·
07/30
美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測
路透中文
·
07/27
美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場 開盤後升逾59%
智通财经
·
07/24
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/HELX/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":40.9874,"timestamp":1789156800000,"preClose":41.0314,"halted":0,"volume":368,"hourTrading":{"tag":"盘后","latestPrice":41.11,"preClose":40.9874,"latestTime":"19:30 EDT","volume":9,"amount":368.8866,"timestamp":1789169407282,"change":0.1226,"changeRate":0.002991,"amplitude":0},"delay":0,"changeRate":-0.0010723494689432224,"floatShares":750000,"shares":750000,"eps":0,"marketStatus":"休市中","change":-0.044,"latestTime":"09-11 16:00:00 EDT","open":41.11,"high":41.11,"low":40.9874,"amount":15142.14752,"amplitude":0.002988,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":41.0314,"sharesOutstanding":650000,"nav":40.977,"aum":30732469.75,"dividendRate":0.003504,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":41.11,"preClose":40.9874,"latestTime":"19:30 EDT","volume":9,"amount":368.8866,"timestamp":1789169407282,"change":0.1226,"changeRate":0.002991,"amplitude":0},"volumeRatio":0.20772183806100336,"impliedVol":0.1357,"impliedVolPercentile":0.5777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":750000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.20772183806100336,"shares":750000,"dividePrice":0.1436,"high":41.11,"amplitude":0.002988,"preClose":41.0314,"low":40.9874,"week52Low":29.8,"pbRate":"--","week52High":43.5089,"institutionHeld":0,"latestPrice":40.9874,"eps":0,"divideRate":0.003504,"volume":368,"delay":0,"ttmEps":0,"open":41.11,"prevYearClose":36.3062,"prevWeekClose":41.8884,"prevMonthClose":41.805,"prevQuarterClose":39.9651,"fiveDayClose":42.3102,"twentyDayClose":40.75,"sixtyDayClose":35.8162},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660790477","title":"A股異動 | 華大智造(688114.SH)早盤漲20%封漲停 基因測序有望成為mRNA個性化腫瘤疫苗「底層基礎設施「","url":"https://stock-news.laohu8.com/highlight/detail?id=2660790477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660790477?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 10:36","pubTimestamp":1787193395,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华大智造开盘后快速封涨停。截至发稿，涨20%，报69.11元，成交额4.28亿元。消息面上，Moderna与默沙东联合研发的个性化mRNA癌症疫苗在大型三期临床试验中取得成功，引爆全球mRNA肿瘤疫苗赛道。这意味着，基因测序作为个性化肿瘤疫苗\"底层基础设施\"的价值，正迎来战略重估。公开资料显示，华大智造为国产基因测序龙头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399300","GNMX","02827","07233","159646","159982","03188","82846","BK0251","83130","83188","WDNA","02846","688114","BK1147","HELX","SYNB","03130","GNOM","GDOC","HTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660421558","title":"第3次更新-足球——謝菲爾德聯隊前所有者獲准申請清算當初收購該俱樂部的那家公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660421558","media":"路透中文","labels":["policyRegulatory","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660421558?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:49","pubTimestamp":1787150961,"startTime":"0","endTime":"0","summary":"第3次更新-足球——谢菲尔德联队前所有者获准申请清算当初收购该俱乐部的那家公司在第4至5段中补充了谢菲尔德联队的声明路透伦敦8月19日-谢菲尔德联队前所有者周三获准申请，将清算该公司——该公司在2024年收购了这支英冠球队。谢菲尔德联队表示，高等法院的裁决对俱乐部而言并非问题。但今年6月，谢菲尔德联队表示1919 Partners LLC是该俱乐部的母公司，对此，United World本周表示，此举“似乎是试图逃避向CSBL的债权人付款”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G1AH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","GNOM","LU0109394709.USD","LU0320765992.SGD","FFOX","PTH","GH","LFSC","BK4588","HELX","BK4535","LU0889565916.HKD","GNMX","EKG","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172077351","title":"Natera助力新臨床研究：利用Latitude™評估晚期皮膚癌ctDNA動態變化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172077351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172077351?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:02","pubTimestamp":1786528935,"startTime":"0","endTime":"0","summary":"Natera将支持一项全新临床试验，旨在评估Latitude™技术在晚期皮肤癌中监测循环肿瘤DNA（ctDNA）动态变化的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0012050646.USD","LU0106261612.USD","LU0053671581.USD","LU2324357040.USD","LU0963586101.USD","LU2065170008.USD","LU2264538146.SGD","LU2065171402.SGD","LU1064131342.USD","HELX","BK4139","LU0345770993.USD","NTRA","GNOM","LU2065731478.USD","LU1988902786.USD","LU0345770308.USD","LU2065171311.SGD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658292607","title":"韓國公布七項戰略技術項目 涵蓋核能、量子計算、太空、生物技術等領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2658292607","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658292607?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 14:07","pubTimestamp":1786514821,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["CRTC","XQTM","NLR","URNJ","BK4585","QTUP","BK4606","BK4588","QTUM","HELX","SRUUF","NUKZ","WDNA","CQTM","URAN","CHPX","URA","WQTM","URNM","LOUP","QPUX","SPRX","QUA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658595928","title":"我國綠色燃料產業從「示範試點」走向「規模量產」","url":"https://stock-news.laohu8.com/highlight/detail?id=2658595928","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658595928?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 10:14","pubTimestamp":1786500840,"startTime":"0","endTime":"0","summary":"郭晓波认为，2026至2030年是我国绿色燃料产业从示范试点走向规模化应用的关键窗口期，当前绿色燃料市场已进入政策与需求“双轮”驱动阶段，碳价上行将持续收窄绿色燃料与传统燃料的价差。龙基能源集团致力于打破成本与效率“瓶颈”，助力我国绿色燃料产业从“示范试点”走向“规模量产”，为填补国内高端绿色航煤产能缺口贡献核心力量。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-12/doc-inimzivu5413675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658550947","title":"中賦科技成立靈源生物技術公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2658550947","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658550947?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 09:35","pubTimestamp":1786498517,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658677969","title":"風暴眼 | 6歲女童基因治療死亡：急於追逐「全球首例」的代價","url":"https://stock-news.laohu8.com/highlight/detail?id=2658677969","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658677969?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 21:40","pubTimestamp":1786282855,"startTime":"0","endTime":"0","summary":"事件背后，关于基因编辑与“追逐全球首例”的风险、其中的伦理边界之争，才刚刚开始。一周后，小美死亡。患者家属为试验和治疗自费的巨额花销，是另一重争议。“世界首例”的光环，的确十分诱人。也许是低估了高剂量AAV的免疫反应风险，也许是“全球首例”的诱惑压过了审慎，小美在时机尚不成熟的时候，被推上了手术台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8vSOZR7YZVA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","ARDS","BK4139","SYNB","AAU","WDNA","FWD","XT","HELX","NBDS","GNOM","TARK","DTEC","BMED","BK4168","KOMP","BK4079","AAMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657695946","title":"半月內兩起兒童基因編輯試驗死亡事件曝光，業內警示：追求「全球首創」不能忽視臨床安全與合規要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2657695946","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657695946?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 12:00","pubTimestamp":1786075247,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","FWD","HELX","KOMP","DTEC","XT","NBDS","GNOM","WDNA","TARK","IDNA","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657413405","title":"新聞8點見丨影院屏攝亂象背後的三角困局；女童基因編輯悲劇中倫理為何失守","url":"https://stock-news.laohu8.com/highlight/detail?id=2657413405","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657413405?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 19:31","pubTimestamp":1785929460,"startTime":"0","endTime":"0","summary":"新闻8点见，多一点洞见。世界卫生组织临时专家组成员、世界卫生组织人类基因编辑治理和监督全球标准专家咨询委员会成员、国家科技伦理委员会委员翟晓梅。本次被广泛关注和报道的事件属于体细胞基因编辑。8月5日，中国气象局发文回应称，高温低报或高温不报是不存在的。体感温度和预报气温的差异，或许是人们质疑的原因。","market":"sh","thumbnail":"https://media.bjnews.com.cn/cover/2026/08/05/5749141873621018263.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2026/08/05/5749141873621018263.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1785925616129444.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1785925616129444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["FWD","XT","GNOM","WDNA","HELX","SYNB","IDNA","NBDS","TARK","DTEC","BMED","KOMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656584164","title":"AI賦能肺癌早篩診療升級 國產醫療機器人加速精準醫療落地 真健康醫療(02697)迎行業發展機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2656584164","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656584164?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 12:58","pubTimestamp":1785819500,"startTime":"0","endTime":"0","summary":"业内人士认为，随着AI影像识别、三维重建、机器人辅助介入等技术持续成熟，医疗机器人产业正加速迈入商业化应用阶段，覆盖肺癌、骨科、神经外科等多个高价值赛道，行业成长空间广阔。受益于医疗智能化升级趋势，“穿刺手术机器人第一股”真健康医疗持续推进人工智能与数字医疗布局。随着国家持续推动医疗数字化建设，以及AI医疗机器人、精准诊疗等新技术加速落地，真健康医疗有望受益于行业景气度提升，进一步打开长期成长空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VTHR","TYNE","BMED","SYNB","BK1100","KOMP","WDNA","HELX","02697","ARTY","HTEC","159891","QTOC","CHAT","AIPO","GNMX","XT","GDOC","DTEC","GNOM","IDNA","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585241","title":"港股異動 | 凱萊英升逾8%，近日擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585241","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656585241?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:35","pubTimestamp":1785807328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，凯莱英高开逾5%，截至发稿，涨5.5%，报115港元，成交额319.7万港元。消息面上，近日，凯莱英发布公告，该公司、目标公司上海凯莱英生物技术发展有限公司、凯莱英生物技术、高瓴祈睿、珠海岱恒、Hao Hong博士、凯莱同心及海河凯莱英基金订立增资协议，据此，该公司及投资者同意向目标公司股本增资，总额为人民币12.397亿元，公司、高瓴祈睿、Hao Hong博士分别出资10.5亿元、1.77亿元及1270万元。","market":"us","thumbnail":"https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c5f6cd84096ca9b3b893fb788b76d134"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475561.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","06821","BK0132","002821","BK1191","VXUS","LU1328615791.USD","BK0239","WDNA","HELX","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303576","title":"專注腫瘤領域的生物技術公司BlossomHill Therapeutics計劃通過首次公開募股募資約1.328億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303576?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 00:41","pubTimestamp":1785775260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","IPO","QQQS","BCSM","HELX","LENZ","BK4139","LQPE","BK4007","ACSG","BK4539","PEVC","SPCK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037309","title":"基因編輯的商業化：一款產品220萬美元，A股超20家概念股，但多數只賣工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037309","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656037309?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 18:53","pubTimestamp":1785754410,"startTime":"0","endTime":"0","summary":"红星资本局8月3日消息，近日，一名6岁女童在接受基因编辑临床试验后死亡的事件，将“基因编辑”这项前沿技术推向公众视野。红星资本局注意到，近年来，基因编辑这一创新医疗技术在β-地中海贫血、镰状细胞贫血病等遗传性疾病治疗领域已有成熟应用，国外也有获批上市的药物。在国内，目前布局基因编辑疗法的主要为新兴的生物科技公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033829926851.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033829926851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["WDNA","HELX","IDNA","159982","XT","DTEC","NBDS","TARK","399300","FWD","SYNB","KOMP","GNOM","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655389842","title":"市場消息：日本政府計劃將西日本打造為生物技術與高端醫藥領域的投資集聚中心。","url":"https://stock-news.laohu8.com/highlight/detail?id=2655389842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655389842?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 04:50","pubTimestamp":1785444630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655803495","title":"凱萊英(06821)擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655803495","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655803495?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 21:53","pubTimestamp":1785419628,"startTime":"0","endTime":"0","summary":"智通财经APP讯，凯莱英 公布，于2026年7月30日，该公司、目标公司上海凯莱英生物技术发展有限公司、凯莱英生物技术、高瓴祈睿、珠海岱恒、Hao Hong博士、凯莱同心及海河凯莱英基金订立增资协议，据此，该公司及投资者同意向目标公司股本增资，总额为人民币12.397亿元，公司、高瓴祈睿、Hao Hong博士分别出资10.5亿元、1.77亿元及1270万元。于增资完成后，目标公司将由公司拥有约83.50%的权益，并仍为公司的非全资附属公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002821","WDNA","06821","LU1328615791.USD","BK0132","HELX","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655491803","title":"凱萊英(06821.HK)擬向上海凱萊英生物技術發展增資10.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655491803","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655491803?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 21:53","pubTimestamp":1785419628,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655821999","title":"代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655821999","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655821999?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 16:15","pubTimestamp":1785399353,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发内分泌和代谢紊乱疾病疗法、正处于2b期临床阶段的生物技术公司Vogenx于周三公布了其首次公开募股条款。这家总部位于北卡罗来纳州罗利市的公司计划通过以每股11至13美元的价格区间发行630万股股票，募集7500万美元资金。按拟议区间中点计算，Vogenx的完全稀释后市值将达到1.73亿美元。JonesTrading担任此次交易的唯一账簿管理人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474046.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["UUP","WDNA","HELX","UDN","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655821967","title":"代謝紊亂生物技術公司Vogenx(VOGX.US)IPO定價11-13美元/股 擬募資7500萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2655821967","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655821967?lang=zh_tw&edition=fundamental","pubTime":"2026-07-30 16:15","pubTimestamp":1785399353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UDN","HELX","WDNA","UUP","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048086","title":"美國食品藥品監督管理局（FDA）批准了Freenome公司用於結直腸癌篩查的血液檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048086","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048086?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 21:13","pubTimestamp":1785157998,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准了Freenome公司用于结直肠癌筛查的血液检测路透7月27日-两家公司周一表示，美国食品药品监督管理局已批准Freenome公司针对年龄较大的成年人的FRNM.O血液结直肠癌筛查检测，为合作伙伴雅培公司今秋在美国推出该产品铺平了道路。美国食品药品监督管理局批准该检测适用于45岁及以上中风险成年人，这使Freenome拥有了其首个商业化产品。根据2025年签署的商业化协议，Freenome将从雅培公司获得与此次批准相关的1亿美元里程碑付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL4T43T12N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0320765992.SGD","PTH","LU1721429741.USD","LU0170899867.USD","LU0058720904.USD","LU0889565916.HKD","SG9999002224.SGD","LU0122379950.USD","BK4585","LU2237957902.USD","SG9999004303.SGD","GH","GDOC","BK4535","BK4568","SG9999002232.USD","LU1914381329.SGD","LU1989763690.USD","LU1061106388.HKD","ABT","LFSC","LU0266013472.USD","LU2237957811.SGD","SGXZ23171101.USD","PJP","GNMX","HELX","LU2112291526.USD","EKG","LU0234572021.USD","BK4082","LU0882574055.USD","LU1989763427.SGD","IE00BJJMRZ35.SGD","LU2468319806.SGD","LU2133065610.SGD","LU0868494617.USD","TMED","BK4551","FFOX","GNOM","BK4533","IE00B2B36J28.USD","BK4588","LU2211815571.USD","LU0432979614.USD","FRNM","IE0002141913.USD","IHI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654036699","title":"美股異動 | CRISPR基因編輯公司Scribe Therapeutics(SCTX.US)登陸美股市場 開盤後升逾59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654036699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654036699?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 23:57","pubTimestamp":1784908651,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","TARK","BK4539","BK4556","FWD","SYNB","LU1861559042.SGD","ARKG","NBDS","BK4007","DTEC","WDNA","KOMP","BMED","BK4139","SCTX","LENZ","BK4588","XT","BK4611","BK4585","HELX","LU1861558580.USD","CRSP","IDNA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}